An update on current and future treatment options for chondrosarcoma

MacDonald, Iona; Lin, Chih-Yang; Kuo, Sheng‐Fong; Su, Chen-Ming; Tang, Chih-Hsin

doi:10.1080/14737140.2019.1659731

Cited by 45 publications

(36 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All data were collected from 18 local cancer registries, representing the total US population. SEER*Stat [12] (version 8.3.5; National Cancer Institute, Bethesda, MD, USA) was used to acquire clinical data. The following information was collected in a uni ed form for each case: patient ID, sex, year of diagnosis, age at diagnosis, race, histology, stage, grade, type of surgery, cause of death, and COD (cause of death) to site recode.…”

Section: Methodsmentioning

confidence: 99%

Prognostic Factors in Conventional Chondrosarcoma Patients: a SEER Database Analysis

Gao

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Conventional chondrosarcoma, a rare type of bone tumor, was resistant to chemotherapy and radiation therapy, so more characteristics were needed. In clinic, the use of small series and single-institution studies have limited the investigation of chondrosarcoma. The Surveillance, Epidemiologic, and End Results is the most complete and comprehensive database worldwide. Based on this database, the study aimed to collect clinicopathological features and detect the prognosis of patients with conventional chondrosarcoma. Methods: Clinicopathologic and survival data of 782 patients from 2010 to 2016 and 353 patients from 2007 to 2009 were downloaded and analyzed. Overall survival was analyzed using the Kaplan-Meier method and verified by univariable Cox regression, and independent prognostic factors were assessed using the multi-variable Cox regression hazards model. Then, nomogram was established and the one-, three-, and five-year survival rates could be calculated with the nomogram. Competitive risk models were conducted to identify prognostic risk factors related to competitive endpoint events in patients with conventional chondrosarcoma. Results: In total, 361 extremities, 360 axial bones, and 61 cranial samples were collected from the 2010 to 2016 cohort. The median survival time of patients with conventional chondrosarcoma was 35 months, and the independent prognostic factors were sex, grade, surgery, AJCC_M age, and tumor size. Thereafter, a nomogram was established based on those independent prognostic factors. The competitive risk model revealed no competitive risk for the cancer specific endpoint event. Those data from 2007 to 2009 were used to validate the results from 2010 to 2016 with general consistency. This retrospective study determined the prognostic factors in patients with conventional chondrosarcoma using the Cox regression hazards model. A nomogram was established to help oncologists assess this rare malignant tumor with low heterogeneity.Conclusions: In the study, independent prognostic risk factors for conventional chondrosarcoma were identified, and a nomogram predicting three- and five- year overall survival rates were established, which may help physicians to predict the prognosis of patients with chondrosarcoma.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic Factors in Conventional Chondrosarcoma Patients: a SEER Database Analysis

Gao

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic Factors in Patients with Conventional Chondrosarcoma: A SEER Database Analysis

Gao

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Conventional chondrosarcoma, a rare type of bone tumor, is resistant to chemotherapy and radiation therapy. Thus, additional characteristics of this disease are needed to open other treatment modalities. The clinical investigation of chondrosarcoma is limited to small-series and single-institution studies. The Surveillance, Epidemiologic, and End Results (SEER) is the most complete and comprehensive database worldwide. This SEER database study aimed to collect clinicopathological features and determine the prognosis of patients with conventional chondrosarcoma. Methods: Clinicopathologic and survival data of 782 patients from 2010 to 2016 and 353 patients from 2007 to 2009 were downloaded and analyzed. Overall survival was analyzed using the Kaplan–Meier method and verified by univariable Cox regression. Independent prognostic factors were assessed using the multi-variable Cox regression hazards model. A nomogram was established and used to calculate the one-, three-, and five-year survival rates. Competitive risk models were established to identify the prognostic risk factors related to competitive endpoint events in patients with conventional chondrosarcoma. Results: In total, 361 extremities, 360 axial bones, and 61 cranial samples were collected from the 2010–2016 cohort. The median survival time of patients with conventional chondrosarcoma was 35 months, and the independent prognostic factors were sex, grade, surgery, AJCC_M age, and tumor size. Thereafter, a nomogram was established basing from those independent prognostic factors. The competitive risk model revealed no competitive risk for the cancer-specific endpoint event. The data from 2007 to 2009 were used to validate the results from 2010 to 2016 with general consistency. Conclusion: This retrospective study determined the prognostic factors in patients with conventional chondrosarcoma by using the Cox regression hazards model. A nomogram was established to help oncologists assess this rare malignant tumor with low heterogeneity.

show abstract

“… 2 Thus, novel targeted therapies based upon the molecular mechanisms of chondrosarcoma development, representing a novel relevant therapeutic approach, will open new treatment options by targeting several signaling pathways responsible for the biological processes such as proliferation, differentiation and apoptosis. 3 …”

Section: Introductionmentioning

confidence: 99%

Identification of ZNF704 as a Novel Oncogene and an Independent Prognostic Marker in Chondrosarcoma

Chen¹,

Zhou²,

Zhang³

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose The transcription factor zinc finger protein 704 (ZNF704) is implicated in tumorigenesis. However, the underlying role of ZNF704 in the pathogenesis of chondrosarcoma remains not well delineated. This study investigates the expression level, prognostic significance and potential biological function of ZNF704 in human chondrosarcoma. Materials and Methods The mRNA and protein levels of ZNF704 in fresh chondrosarcomas and the paired adjacent non-tumor tissues were evaluated using real-time PCR and immunoblotting, respectively. The protein expression of ZNF704 in chondrosarcoma specimens was detected by immunohistochemistry, and the associations among its expression level, clinicopathological characteristics and prognosis were further investigated. Cell viability, colony formation and apoptosis assay were determined in chondrosarcoma cells and a xenograft model with ZNF704 knockdown. Results The expression levels of ZNF704 mRNA and protein in chondrosarcoma tissues were significantly higher than those in the paired adjacent non-tumor tissues and benign cartilage tumors. Clinicopathological analysis revealed that ZNF704 was expressed at higher levels in chondrosarcoma patients with higher histological grade and advanced MSTS stage. We also found that high expression of ZNF704 significantly correlated with a worse overall survival of chondrosarcoma patients. Multivariate Cox regression analysis indicated that ZNF704 was an independent prognostic marker in chondrosarcoma patients. Our in vitro studies demonstrated that knockdown of ZNF704 markedly inhibited chondrosarcoma cell viability, colony formation and induced apoptosis. In a nude mouse xenograft model, ZNF704 knockdown slowed down chondrosarcoma growth by inducing apoptosis in vivo. Conclusion These findings suggest that ZNF704 may act as a potent oncogene implicated in chondrosarcoma development, and serve as a independent prognostic marker, highlight the potential of ZNF704 as a novel biomarker and therapeutic target for chondrosarcoma.

show abstract

An update on current and future treatment options for chondrosarcoma

Cited by 45 publications

References 90 publications

Prognostic Factors in Conventional Chondrosarcoma Patients: a SEER Database Analysis

Prognostic Factors in Conventional Chondrosarcoma Patients: a SEER Database Analysis

Prognostic Factors in Patients with Conventional Chondrosarcoma: A SEER Database Analysis

Identification of ZNF704 as a Novel Oncogene and an Independent Prognostic Marker in Chondrosarcoma

Contact Info

Product

Resources

About